General
Preferred name
PHENOXYBENZAMINE
Synonyms
PHENOXYBENZAMINE HYDROCHLORIDE ()
Benzenemethanamine, n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)- ()
CPD000058422 ()
NCI-c01661 ()
NSC 37448 ()
Phenoxybenzamine HCl ()
Dibenzyline63-92-3 ()
DIBENYLINE ()
Phenoxybenzamine (hydrochloride) ()
NSC 37448, NCI-c01661 ()
DIBENZYLIN ()
DIBENZYLINE ()
DIBENZYLINE CHLORIDE ()
DIBENZYLINE HYDROCHLORIDE ()
DIBENZYRAN ()
NSC-37448 ()
PHENOXYBENZAMINE CHLORIDE ()
Dibenylin ()
Benzylyt ()
Fenoxibenzamina ()
Bensylyt ()
Phenoxybenzamine-d5 (hydrochloride) ()
P&D ID
PD009637
CAS
63-92-3
59-96-1
102737-84-8
34238-85-2
1329838-45-0
Tags
available
drug
Approved by
FDA
First approval
1953
Drug indication
adrenal gland pheochromocytoma
Cardiovascular disease
Malignant essential hypertension
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active ¦Á-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity[1][2].
DESCRIPTION Phenoxybenzamine is a non-selective, irreversible alpha blocker (α-adrenoceptor antagonist). (GtoPdb)
DESCRIPTION Selective alpha adrenoceptor blocking agent; calmodulin antagonist (LOPAC library)
DESCRIPTION Phenoxybenzamine HCl is a non-specific, irreversible alpha antagonist with an IC50 of 550 nM. (BOC Sciences Bioactive Compounds)
DESCRIPTION Phenoxybenzamine hydrochloride (NCI-c01661) is the hydrochloride salt form of phenoxybenzamine, a synthetic, dibenzamine alpha-adrenergic antagonist with antihypertensive and vasodilatory properties. Phenoxybenzamine non-selectively and irreversibly blocks the postsynaptic alpha-adrenergic receptor in smooth muscle, thereby preventing vasoconstriction, relieving vasospasms, and decreasing peripheral resistance. Reflex tachycardia may occur and may be enhanced by blockade of alpha-2 receptors which enhances norepinephrine release. Phenoxybenzamine is reasonably anticipated to be a human carcinogen. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
2
Compound Sets
36
AdooQ Bioactive Compound Library
Bioprocess diversity set
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Ki Database
LOPAC library
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
External IDs
97
Properties
(calculated by RDKit )
Molecular Weight
303.14
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
8
Ring Count
2
Aromatic Ring Count
2
cLogP
4.19
TPSA
12.47
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.68
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
alpha
Biological process
Resipration, oxidative phosphorylation, & mitochondrial targeting
Target
Adrenergic Receptor
CAM
α-adrenergic receptor
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C
Member status
virtual
MOA
alpha-Adrenoceptor Antagonists
Adrenergic Receptor antagonist
Indication
hypertension, pheochromocytoma
Disease Area
cardiology, endocrinology
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Therapeutic Class
Antihypertensive Agents
Recommended Cell Concentration
10 uM
Source data